Abstract:Aims/hypothesis: MicroRNAs are being sought as biomarkers for the early identification of type 2 diabetes. This study aimed to synthesise the evidence from microRNA-type 2 diabetes association studies and microRNA-regulated type 2 diabetes pathway delineation studies that met stringent quality criteria to identify and validate microRNAs of both statistical and biological significance as type 2 diabetes biomarkers. Methods: Eligible controlled studies on microRNA expression profiling of type 2 diabetes were retrieved from PubMed, ScienceDirect and Web of Science. MicroRNA-regulated type 2 diabetes pathway delineation studies were conducted by integrating and cross-verifying the data from miRTarBase, TransmiR, miRecords, TargetScanHuman, the Kyoto Encyclopedia of Genes and Genomes (KEGG) and the Retraction Watch database. Before meta-analysis, quality assessment was performed according to the corresponding reporting guidelines for evidence-based medicine. To select the most statistically significant microRNAs, we conducted extensive meta-analyses according to the latest methodology. Subgroup and sensitivity analyses were carried out to further examine the microRNA candidates for their tissue specificity and blood fraction specificity and the robustness of the evidence. Signalling pathway impact analysis of dysregulated microRNAs identified from meta-analyses was performed to select biologically significant microRNAs that were enriched in our newly built microRNA-regulated pathways. Results: Of the 404 differentially expressed microRNAs identified in the 156 controlled profiling studies with a combined sample size of >15,000, only 60 were both consistently and significantly dysregulated in human type 2 diabetes. No microRNAs were both consistently and significantly dysregulated in multiple tissues according to subgroup analyses. In total, 58 microRNAs were found to be robust in sensitivity analyses. A total of 1966 pathway delineation studies were identified, including 3290 microRNA-target interactions, which were further combined with KEGG pathways, producing 225 microRNA-regulated pathways. Impact analysis found that 16 dysregulated microRNAs identified from extensive meta-analyses were statistically significantly enriched in the augmented KEGG type 2 diabetes pathway. Conclusions/interpretation: Sixteen microRNAs met the criteria for biomarker selection. In terms of both significance and relevance, the order of priority for verification of these microRNAs is as follows: miR-29a-3p, miR-221-3p, miR-126-3p, miR-26a-5p, miR-503-5p, miR-100-5p, miR-101-3p, mIR-103a-3p, miR-122-5p, miR-199a-3p, miR-30b-5p, miR-130a-3p, miR-143-3p, miR-145-5p, miR-19a-3p and miR-311-3p. Registration: PROSPERO registration number CRD42017081659.

MicroRNAs and Type 2 Diabetes

Relationship between Circulating miRNA and Type 2 Diabetes

Regulatory Roles of MicroRNAs in Diabetes

A comprehensive overview on Micro RNA signature in type 2 diabetes Mellitus and its complications

MicroRNAs in Type 1 Diabetes: Complex Interregulation of the Immune System, β Cell Function and Viral Infections

Exosomal miRNAs and isomiRs: potential biomarkers for type 2 diabetes mellitus

Emerging roles of microRNAs as diagnostics and potential therapeutic interest in type 2 diabetes mellitus

MicroRNA biomarkers of type 2 diabetes: evidence synthesis from meta-analyses and pathway modelling

Research Status of Differentially Expressed Noncoding RNAs in Type 2 Diabetes Patients

MicroRNA Networks in Pancreatic Islet Cells: Normal Function and Type 2 Diabetes

Micro-RNA Implications in Type-1 Diabetes Mellitus: A Review of Literature

Dietary modulation of microRNAs in insulin resistance and type 2 diabetes

MicroRNA-26a Regulates Insulin Sensitivity and Metabolism of Glucose and Lipids.

Recent Highlights of Research on miRNAs as Early Potential Biomarkers for Cardiovascular Complications of Type 2 Diabetes Mellitus

Weighted Gene Coexpression Network Analysis Identified MicroRNA Coexpression Modules and Related Pathways in Type 2 Diabetes Mellitus

Non-Coding RNA as Biomarkers for Type 2 Diabetes Development and Clinical Management

Association of MicroRNA-146a with Type 1 and 2 Diabetes and their Related Complications

Emerging Roles of ncRNAs in Type 2 Diabetes Mellitus: From Mechanisms to Drug Discovery

Abstract P124: Human Small Artery MicroRNA Expression Profiles: Changes in Type 2 Diabetes and Associations with Endothelial Function

Increased MicroRNA-146a Levels in Plasma of Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Study on Serum Levels of miR-1 6,miR-1 2 6 and miR-2 2 1 and Their Clinical Significance in Type 2 Diabetes Patients with or Without Microvascular Complications